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Abstract
The gut microbiota has recently been proposed as a novel component in the regulation of host homeostasis and immunity.
We have assessed for the first time the role of the gut microbiota in a mouse model of leukemia (transplantation of BaF3
cells containing ectopic expression of Bcr-Abl), characterized at the final stage by a loss of fat mass, muscle atrophy,
anorexia and inflammation. The gut microbial 16S rDNA analysis, using PCR-Denaturating Gradient Gel Electrophoresis and
quantitative PCR, reveals a dysbiosis and a selective modulation of Lactobacillus spp. (decrease of L. reuteri and L. johnsonii/
gasseri in favor of L. murinus/animalis) in the BaF3 mice compared to the controls. The restoration of Lactobacillus species by
oral supplementation with L. reuteri 100-23 and L. gasseri 311476 reduced the expression of atrophy markers (Atrogin-1,
MuRF1, LC3, Cathepsin L) in the gastrocnemius and in the tibialis, a phenomenon correlated with a decrease of
inflammatory cytokines (interleukin-6, monocyte chemoattractant protein-1, interleukin-4, granulocyte colony-stimulating
factor, quantified by multiplex immuno-assay). These positive effects are strain- and/or species-specific since L. acidophilus
NCFM supplementation does not impact on muscle atrophy markers and systemic inflammation. Altogether, these results
suggest that the gut microbiota could constitute a novel therapeutic target in the management of leukemia-associated
inflammation and related disorders in the muscle.
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Introduction
The development of cancer is often accompanied by modifica-
tions of host energy homeostasis [1,2]. Up to 50% of cancer
patients suffer from adipose tissue loss and skeletal muscle atrophy
– called cachexia – resulting in a reduced quality of life and in a
shortened survival time [1]. The incidence of cachexia depends on
cancer type [2]. 39% of patients with acute non lymphocytic
leukemia experience weight loss in the six month-period preceding
chemotherapy [3]. Weight loss and anorexia have also been
described in acute childhood lymphoblastic leukemia and in
chronic myeloid leukemia, a pathology characterized, among
other things, by the fusion gene Bcr-Abl [4,5].
The mechanisms implicated in cancer-related fat mass loss are
poorly understood, but possibly imply the activation of adipose
triglyceride lipase and hormone-sensitive lipase [6]. Muscle
atrophy in cancer cachexia has been more extensively studied.
Atrogin-1/Muscle Atrophy F-box (Mafbx) and Muscle RING
Finger 1 (MuRF1), two ubiquitin ligases of the ubiquitin-
proteasome pathway, are markers of skeletal muscle atrophy and
are induced by cancer cachexia [7–9]. Overexpression of Atrogin-
1 in myotubes produces atrophy, whereas mice deficient in
Atrogin-1 and MurF1 are found to be resistant to atrophy [7].
MurF1 is involved in the breakdown of myofibrillar proteins (actin,
myosin heavy chain), whereas, by contrast, Atrogin-1 has a role in
the control of protein synthesis [10–12]. These markers are
therefore considered as potential drug targets for the treatment of
muscle atrophy [7]. The light chain 3 of microtubule-associated
proteins (LC3), essential to autophagosome formation, and
Cathepsin L, a lysosomal protease, are induced in muscle atrophy
mouse models, i.e. amyotrophic lateral sclerosis, and might also be
implied in cancer-related muscle atrophy [9,13]. Several mecha-
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nisms have been proposed to explain the catabolic state associated
with cancer in general: anorexia, futile cycles and increased
thermogenesis. Furthermore, inflammatory mediators, such as
interferon-gamma (IFN-c), interleukin-6 (IL-6) and tumor necrosis
factor-alpha (TNF-a) may contribute to anorexia, adipose tissue
loss and muscle atrophy [1].
The gut microbiota, composed of a hundred trillion bacteria, is
now considered a metabolic community, able to regulate host
physiology and immunity [14,15]. Gut microbes influence local
and systemic inflammation through pattern recognition receptors
[16,17]. It is now clearly established that gut microbes may
regulate fat mass expansion, e.g. through the fermentation
products and the inhibition of the fasting induced adipose factor
[18–22]. Ba¨ckhed et al. also reported an increased AMPK activity
in the muscle of germ-free animals [21]. Moreover, we have shown
that changing the gut microbiota using prebiotics increases muscle
mass in obese and type 2 diabetic mice [22]. These studies suggest
a link between gut microbes and muscle metabolism. However, the
gut microbes-muscle axis remains poorly explored in pathophys-
iological conditions, like cancer cachexia.
Intestinal dysbiosis means ‘‘alterations in the composition and/
or activity of the gut microbiota in comparison to healthy
individuals’’ and has been associated with inflammatory or
metabolic diseases like inflammatory bowel disease, obesity, type
2 diabetes and necrotizing enterocolitis [23]. We have hypothe-
sized that intestinal dysbiosis might also be associated with
leukemia-related cachectic features and that disturbances in the
symbiotic gut microbiota-host relationship might exist in case of
systemic cancer development.
In the present study, we have used a mouse model which mimics
an acute leukemia (iv injection of BaF3 cells transfected with a Bcr-
Abl oncogene) [24,25], and that is characterized by cachectic
symptoms like anorexia, loss of fat mass and muscle atrophy.
Materials and Methods
Ethics Statement
The agreement of the animal experiments performed in this
study was given by the ethical committee for animal care of the
Health Sector of the Universite´ catholique de Louvain, under the
supervision of Prof. F Lemaigre et JP Dehoux under the specific
number 2010/ULC/MD/022. Housing conditions were as
specified by the Belgian Law of April 6, 2010, on the protection
of laboratory animals (Agreement LA 1230314). All efforts were
made to minimize suffering of animals.
Cell Culture
The BaF3 cell line transfected with Bcr-Abl was a gift from Dr.
K. Bhalla (MCG Cancer Center, Medical College of Georgia,
Augusta, GA, USA). The BaF3 cells were maintained in
RPMI1640 medium supplemented with 10% fetal bovine serum
(PAA clone, PAA, Pasching, Austria), streptomycin 100 mg/ml,
penicillin 100 IU/ml, and 1% of non-essential amino acids
solution (Gibco, Inchinnan, Scotland) at 37uC in humidified 5%
CO2. The generation of these cells is described in detail elsewhere
[25,26].
Animals
Female BALB/c mice (5-week-old, Charles River, France) were
housed with two mice per cage in a 12 h light/dark cycle. The
intake of food and water was monitored at least 3 times a week in
all experiments.
After an acclimatization period of 1 week, a saline solution or
BaF3 cells (16106 cells in 0.1 ml saline) were injected in the tail
vein of the anesthetized mice. In a first experiment, 16 mice (8
sham injected mice, 8 mice transplanted with BaF3 cells) were
killed after 13 days. In a second experiment, 20 mice (10 sham
injected mice, 10 mice transplanted with BaF3 cells) were killed
after 14 days. This time frame was chosen in order to avoid animal
sufferance linked to severe under-nutrition and inflammation
occurring the final days preceding animal death, in accordance
with the rules of the ethical committee.
For the dietary restriction experiment (third experiment), 18
mice were divided into two groups: 8 control and 10 dietary
restricted mice (DR). All mice received a sham injection on day 0.
From 10 days after the sham injection, DR mice received the same
relative amount of diet (as a percentage of their baseline
consumption) as the BaF3 mice from the first experiment
described above. Food was divided in two equal portions,
delivered in the morning and in the evening respectively. Mice
were killed after 13 days.
In a fourth experiment, 31 mice were divided into four groups:
8 sham injected control mice, 8 sham injected mice supplemented
with lactobacilli, 8 mice transplanted with BaF3 cells and 7 mice
transplanted with BaF3 cells and supplemented with lactobacilli.
The lactobacilli supplement was a mixture of Lactobacillus reuteri
100-23 and Lactobacillus gasseri 311476 (Institut Pasteur de Lille;
cultured, frozen and quantified after thawing) administrated in the
drinking water at 26108 CFU/ml of each strain, starting the first
day after BaF3 inoculation. Lactobacilli solution was changed
every day and contained in bottles specially designed to allow easy
access to small drinking volumes. Total fat mass was determined
two days before and twelve days after BaF3 inoculation with a
7.5 MHz Time domain-Nuclear magnetic resonance (TD-NMR)
(LF50 minispec, Bruker, Germany). Mice were killed after 13 days.
In a fifth experiment, 35 mice were divided into four groups: 8
sham injected control mice, 9 sham injected mice supplemented
with Lactobacillus acidophilus NCFM, 10 mice transplanted with
BaF3 cells and 8 mice transplanted with BaF3 and supplemented
with L. acidophilus NCFM. L. acidophilus NCFM (kindly gifted by
Metagenics Belgium, Ostende, Belgium) was administrated as
described in the fourth experiment. Mice were killed after 13 days.
Data from a sixth experiment (8 sham injected mice, 8 mice
transplanted with BaF3 cells, killed after 13 days) were added for
the correlation analyses presented in Figure S3.
Blood and Tissue Samples
At the end of the experiments, blood glucose was determined
with a glucose meter (Roche Diagnostics, Mannheim, Germany)
on 3.5 ml of blood collected from the tip of the tail vein. Mice were
anaesthetized with ketamine/xylazine i.p., 100 and 10 mg/kg
respectively, or with isoflurane gas (Abbot, Ottignies, Belgium).
Retro-orbital blood was collected in EDTA tubes, centrifuged
(13000 g, 3 min) and the plasma was stored at 280uC. Mice were
sacrificed using cervical dislocation. The liver was removed and
weighed. A piece of the liver tissue was fixed in formalin for further
histological analysis, and the remaining liver was clamped in liquid
N2 and stored at 280uC. The spleen, adipose tissues, muscles and
cecum content were collected, weighed and frozen in liquid N2.
Tissue mRNA Analyses
Total RNA was isolated from tissues using the TriPure isolation
reagent kit (Roche Diagnostics, Penzberg, Germany). cDNA was
prepared by reverse transcription of 1 mg total RNA using the Kit
Reverse transcription System (Promega, Madison, WI). Real-time
polymerase chain reaction (PCR) was performed with a StepO-
nePlus Real-Time PCR System and software (Applied Biosystems,
Den Ijssel, The Netherlands) using SYBR Green (Applied
Dysbiosis and Leukemia-Related Disorders
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Biosystems and Eurogentec, Verviers, Belgium) for detection. All
samples were run in duplicate in a single 96-well reaction plate,
and data were analyzed according to the 22 DDCT method. The
purity of the amplified product was verified by analyzing the melt
curve performed at the end of amplification. The ribosomal
protein L19 (RPL19) gene was chosen as a reference gene. The
primer sequences for the targeted mouse genes are detailed in
Table S1.
Blood Analyses
Spectrophotometric kits were used to determine plasma
triglycerides and cholesterol concentrations (Diasys, Sopachem,
Brussels, Belgium). Plasma interleukin-4 (IL-4), interleukin-10 (IL-
10), interleukin-6 (IL-6), monocyte chemoattractant protein-1
(MCP-1), interleukin-8 (IL-8) and granulocyte colony-stimulating
factor (G-CSF) were measured using a customized multiplex kit
(Bio-Rad, Nazareth, Belgium) with the Luminex technology (Bio-
Plex, Bio-Rad).
Gut Microbiota Analyses
The gut microbiota composition was assessed by 16S rRNA
gene analyses using PCR followed by denaturing gradient gel
electrophoresis (DGGE), and quantitative polymerase chain
reaction.
Genomic DNA was extracted from the cecal content using a
QIAamp DNA Stool Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. Denaturing Gradient
Gel Electrophoresis (DGGE) was performed on the total bacteria
amplicons that were generated with primers targeting the V3
region of bacterial 16S rRNA gene [27]. The sequences are
reported in Table S1. The PCR mixture (50 ml) contained 5 ml of
106NH4 reaction buffer; 2.5 ml of MgCl2 (50 mM, 0.1 mg/ml);
2.5 ml of a deoxynucleoside triphosphate preparation (containing
each nucleotide at a 2 mM concentration); 1 ml of each primer
(10 mM); 0.25 ml of Taq polymerase (5 U/ml); 36.75 ml of distilled
water and 1 ml of DNA. The PCR program was used as follows: an
initial denaturation at 94uC for 5 min; 30 cycles of denaturation at
94uC for 20 s, annealing at 55uC for 45 s, and extension at 72uC
for 1 min; and a final extension at 72uC for 7 min, followed by
cooling to 4uC. The PCR was verified by mixing 10 ml of the PCR
product with 2 ml of a loading dye and electrophoresing it on a
1.5% (wt/vol) agarose gel for 15 min at 120 V flanked by a 1 kb
DNA ladder (Promega, Madison, WI). The PCR products were
analyzed on a 35% to 60% DGGE gel using a protocol described
by Muyzer et al. [27] and modified as described below.
Electrophoresis was performed for 14 h at 85 V in 16 TAE
buffer at a constant 60uC temperature using a Dcode system
(Model DGGE-2001, CBS Scientific Company). The gel was
stained with SYBR Gold (20 ml of SYBR Gold in 250 ml of 16
TAE buffer) for 30 min; this was followed by examining the
DGGE band profiles under a UV light. Digital image capturing
was performed using a UVtec UVIdoc gel documentation system.
The DGGE fingerprints obtained were analyzed using FPQuest
software (Bio-Rad, Hercules, CA).
Quantitative PCR was performed as described in ‘‘Tissue
mRNA analyses’’. To detect some Lactobacillus spp. (Lactobacillus
spp. [I] in the first experiment, third experiment), Bifidobacterium
spp. and Bacteroides spp., we used probes and a TaqMan Universal
PCR Master Mix, as described previously [28]. The primers and
probes are detailed in Table S1. The cycle threshold of each
sample was then compared with a standard curve (performed in
triplicate) made by diluting genomic DNA (five-fold serial dilution)
(BCCM/LMG, Ghent, Belgium and DSMZ, Braunshweig,
Germany). Prior to isolating the DNA, the cell counts were
determined in culture and expressed as ‘‘colony-forming unit’’
(CFU). For L. johnsonii/gasseri, L. reuteri and L. murinus/animalis,
standard DNA was quantified based on L. acidophilus DNA.
Statistical Analyses
Results are presented as the mean 6 SEM. Statistical
significance of differences between groups was assessed either by
a Student’s t-test when comparing 2 groups or by one-way
ANOVA followed by post hoc Tukey’s multiple comparison test
when comparing 3 groups or more. Correlations between
parameters were assessed by the Pearson’s test. The food intake
evolution was analysed by two-way ANOVA followed by
Bonferroni post hoc test. P,0.05 was considered statistically
significant. All analyses were performed with GraphPad Prism 5.0
(GraphPad Software, San Diego, CA), except for the principal
component analysis, performed with R [29].
Results
Mice Transplanted with BaF3 Cells (BaF3 mice) Present
Cancer Cell Infiltration in the Liver and the Spleen, and
Develop Muscle Atrophy and Fat Loss
Mouse pro-B BaF3 cells containing ectopic expression of Bcr-
Abl cells were transplanted into mice resulting in an aggressive
malignancy that mimicked acute leukemia, which was character-
ized by an accumulation of BaF3 cells in the liver and spleen.
Leukemia progression was evaluated based on the liver and spleen
weight increase, Bcr-Abl mRNA expression in both organs and
histological analysis of the liver parenchyma (Figure 1).
BaF3 mice exhibited a reduced food intake from 10 days after
the transplantation (Figure S1A, B). Mice were sacrificed 13 days
after the transplantation. BaF3 transplantation decreased adipose
tissues weight (subcutaneous adipose tissue: CT: 305620 mg;
BaF3:222620 mg; n= 8, p = 0,01 and ovarian adipose tissue: CT:
257621 mg; BaF3:133616 mg; n= 8, p,0,001). The atrophy
marker expression, namely Atrogin-1, MuRF1, LC3 and Cathep-
sin L, was induced in the gastrocnemius muscle of BaF3 mice by
1.3-fold to 5-fold after 13 days without any changes in muscle mass
(Table 1). After 14 days, the atrophy marker expression was
further induced and muscle mass loss appeared significant. We
thus concluded, in accordance with previously reported in vivo
kinetics [8,30], that Atrogin-1, MuRF1, LC3 and Cathepsin L are
valuable early markers of muscle atrophy in this mouse model of
leukemia.
BaF3 Mice are Characterized by Changes in Gut
Microbiota Composition Occurring Regardless of the
Food Intake
To assess the presence of intestinal dysbiosis, the gut microbial
composition was assessed by PCR-denaturing gradient gel
electrophoresis (DGGE) and by qPCR of 16S rRNA gene
sequences for total bacteria, Lactobacillus spp., Bifidobacterium spp.
(two Gram-positive genera known for their anti-inflammatory
properties [31,32]) and Bacteroides spp. (a predominant Gram-
negative genus). The DGGE fingerprints for total bacteria
revealed two separate clusters of mice, with the BaF3 mice
clustering separately from the control mice (Figure 2A). Total
bacteria and Bacteroides spp. were present at similar levels in the
cecal content of the control mice and the BaF3 mice, whereas the
lactobacilli levels were reduced in the BaF3 mice versus the control
mice (Figure 2B). The lack of bifidobacteria (data not shown)
appears to be a distinctive feature of young BALB/c mice [33].
Dysbiosis and Leukemia-Related Disorders
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As the melt curve shape difference suggested a change in the
proportions of the species within the Lactobacillus genus (Figure S2),
the common murine Lactobacillus species were enumerated by
qPCR using specific species-targeting primers. Lactobacillus johnso-
nii/gasseri and Lactobacillus reuteri were significantly decreased
whereas Lactobacillus murinus/animalis were not modified
(Figure 2C). The level of each of these species could also be
expressed as a percentage of the total Lactobacillus population
(Figure 2D); the 3 species comprised 70 to 79% of the lactobacilli
present. Expressed in percentage, the relative ratio of Lactobacillus
species found in the BaF3 mice was modified in favor of L.
murinus/animalis at the expense of L. johnsonii/gasseri and L. reuteri. L.
acidophilus and L. helveticus were also tested but represented less than
1% of the lactobacilli present (data not shown). Interestingly, a
highly significant negative correlation was found between the level
of lactobacilli in the cecal content and the atrophy marker
expression in the gastrocnemius muscle (Atrogin-1, MurF1, LC3
and Cathepsin L) (Figure S3).
The decreased food intake observed at the end of the
experiment could theoretically contribute to the decreased level
of Lactobacillus spp., e.g. through the changes of substrates available
for bacterial fermentation. To explore this hypothesis, a separate
set of experiments was performed. Mice were dietary restricted for
the last three days, as demonstrated in the food intake graph
(Figure S1A, B). No differences in the cecal levels of Bacteroides spp.,
total lactobacilli or specific lactobacilli species were observed
between dietary-restricted and ad libitum-fed mice (Figure S1C).
This set of data thus demonstrate that intestinal dysbiosis occurs in
leukemic mice, independently of the reduced food intake.
Figure 1. Transformed mouse proB BaF3 cells infiltrate the liver and spleen. A. Liver and spleen weights. N = 8. *p,0.05 vs. control. B. Bcr-
Abl mRNA levels in liver and spleen, ND: not detected. C. Histological analysis of liver tissue (hematoxylin-eosin staining). Bar = 50 mm. White arrows
indicate BaF3 cells.
doi:10.1371/journal.pone.0037971.g001
Table 1. Tissue weight and atrophy marker expression in the
gastrocnemius muscle.
13 days 14 days
Control
mice BaF3 mice
Control
mice BaF3 mice
Tissue weight
Tibialis (mg) 3161 3161 3161 2561*
Gastrocnemius (mg) 9661 9561 9861 8061*
Markers of muscle atrophy (mRNA expression)
Atrogin-1 1.0060.10 4.9660.78* 1.0060.09 6.9860.99*
MuRF1 1.0060.06 1.6360.25* 1.0060.05 6.8360.70*
LC3 1.0060.03 1.3360.07* 1.0060.03 1.7260.10*
Cathepsin L 1.0060.03 1.9460.27* 1.0060.04 5.0760.43*
N= 8–10,
*p,0.05 versus control mice.
doi:10.1371/journal.pone.0037971.t001
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Figure 2. Changes in gut microbiota composition occur in mice transplanted with BaF3 cells. A. DGGE profiles of the bacterial DNA
isolated from the cecal content. Each profile corresponds to one animal. UPGMA dendogram with Dice coefficient. B. Levels of total bacteria,
Bacteroides spp. and Lactobacillus spp. (quantified with two different sets of primers). C. Lactobacillus johnsonii/gasseri, Lactobacillus murinus/animalis
and Lactobacillus reuteri levels. D. Relative proportions of each Lactobacillus species, expressed as a percentage of the Lactobacillus spp. levels
(second primer set). N = 8, *p,0.05 vs. control. Percentages of each species of lactobacilli are significantly different (p,0.05 with Student’s t-test)
between control mice (CT) and mice transplanted with BaF3 cells (BaF3 mice).
doi:10.1371/journal.pone.0037971.g002
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Supplementation with Lactobacillus reuteri 100-23 and
Lactobacillus gasseri 311476 Decreases Pro-inflammatory
Cytokines and the Expression of Muscle Atrophy Markers
To evaluate the relevance of the drop in lactobacilli to the
cachectic features occurring in the BaF3 mice, we set up an in vivo
experiment consisting of a supplementation with two Lactobacillus
strains. Lactobacillus reuteri 100-23 and Lactobacillus gasseri 311476
were chosen because they are members of the predominant
lactobacilli species that were decreased in the BaF3 mice, namely
Lactobacillus reuteri and Lactobacillus johnsonii/gasseri. Moreover, one
of these two strains (L. reuteri 100-23) exhibits immunoregulatory
capacities [34]. Supplementation with a mixture of both strains
(26108 CFU/ml of each strain) restored the Lactobacillus spp. levels
in BaF3 mice, both at the genus and at the species level, without
changing L. murinus count (Figure 3A–D). The daily food intake
was unchanged upon lactobacilli supplementation (Figure 3E).
Lactobacilli supplementation did not impact on either body weight
gain, nor on leukemia progression (similar liver and spleen weight,
and expression of Bcr-Abl in the liver) (Table 2). Lactobacilli did
not counteract the fat mass loss assessed using TD-NMR and by
weighing adipose fat pads. We also measured blood glucose and
lipid parameters. Glycemia and serum cholesterol were decreased
in the BaF3 mice supplemented or not with lactobacilli. Serum
triglycerides were not affected by the presence of leukemia, or by
lactobacilli supplementation.
Knowing the role of some lactobacilli in the control of innate
immunity and inflammation, we quantified the relevant inflam-
matory markers in mice sera. Interleukin 4 (IL-4), interleukin 10
(IL-10), interleukin 6 (IL-6), monocyte chemo-attractant protein 1
(MCP-1), interleukin 8 (IL-8), and granulocyte colony-stimulating
factor (G-CSF) levels were all increased in the BaF3 mice
compared to the control mice (Figure 4A–F). Interestingly,
lactobacilli supplementation reduced the level of IL-4, MCP-1,
G-CSF and IL-6 in the BaF3 mice. IL-10 and IL-8 remained at a
similar elevated level in the BaF3 mice with or without lactobacilli.
The increased production of IL-6 has been implicated in B-cell
malignancies and could play a role in human and rodent cachexia,
as suggested before by results obtained with anti-IL-6 mAb
therapy [35]. Inflammatory mediators have been reported to
potentially contribute to anorexia and muscle atrophy [1]. Since
lactobacilli supplementation decreased IL-6 serum levels, we
analyzed muscle atrophy markers. Supplementation with L. reuteri
100-23 and L. gasseri 311476 lowered the induction of muscle
atrophy markers (Atrogin-1, MuRF1, LC3 and Cathepsin L) in the
gastrocnemius muscle (Figure 5A–D). The induction of atrophy
markers in the tibialis muscle was also reduced by the lactobacilli
supplementation (although not significantly for Atrogin-1,
Figure 5E–H). Lactobacilli supplementation did not significantly
modify gastrocnemius weight but increased by 8% tibialis muscle
weight (p = 0.05, t-test BaF3 versus BaF3-Lrg) (Figure 5I).
A principal component analysis (PCA), taking into account all
lactobacilli-, atrophy- and inflammation-related parameters, shows
no difference between the control mice and the mice supplement-
ed with lactobacilli (p = 0.42, t-test on dimension 1), whereas the
BaF3 mice supplemented or not with lactobacilli constitute two
separate groups (p = 0.0051, t-test on dimension 1) (Figure S4),
further demonstrating that lactobacilli supplementation impacts
on atrophy- and inflammation-related parameters.
Furthermore, the 4 atrophy markers in the gastrocnemius
muscle and the 6 plasma inflammatory proteins are positively
correlated (e.g. MuRF1 expression and serum IL-6: r = 0.81,
Figure 3. Supplementation with Lactobacillus reuteri 100-23 and Lactobacillus gasseri 311476 mixture restores the lactobacilli levels.
A–D. Lactobacillus spp., L. reuteri, L. jonhsonii/gasseri and L. murinus/animalis levels in control mice (CT), in mice receiving lactobacilli (Lrg), in mice
transplanted with BaF3 cells (BaF3) and in mice transplanted with BaF3 cells and receiving lactobacilli (BaF3-Lrg). E. Daily food intake. N= 7–8. Data
with different superscript letters are significantly different (p,0.05). For the food intake, n = 4 and *p,0,05 BaF3 and BaF3-Lrg mice versus CT and Lrg
mice.
doi:10.1371/journal.pone.0037971.g003
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p,0.0001, n= 31), whereas Lactobacillus spp. level is negatively
correlated with the 4 muscle atrophy markers, assessed in the
gastrocnemius muscle, and the 6 plasma inflammatory proteins
(e.g. Lactobacillus spp. and LC3 expression: r =20.84, p,0.001,
n = 31).
The Lactobacilli Effect on Inflammation and Muscle
Atrophy in the BaF3 Mice is Species- or Strain-specific
As beneficial properties of lactobacilli are known to be strain-
specific [36], we also evaluated the effect of Lactobacillus acidophilus
NCFM, a well-known and widely used probiotic strain [37].
Supplementation with L. acidophilus NCFM restored the Lactoba-
cillus spp. level in the cecal content of the BaF3 mice to the values
observed in the control mice (Figure S5A). L. acidophilus NCFM
supplementation had no impact on the liver and spleen weights,
and did not modify markers of muscle atrophy (Atrogin-1 and
Cathepsin L) (Figure S5B-D). Consistently, no modification of
plasma inflammatory markers (IL-4, IL-10, IL-6, MCP-1, IL-8, G-
CSF) were noticed between the BaF3 mice and the BaF3 mice
supplemented with L. acidophilus NCFM (Figure 5E–J).
Discussion
Nowadays, the gut microbiota is considered a salient regulator
of key host functions (energy metabolism, immunity, endocrine
function) in several physiological and pathological conditions
[16,38,39]. To our knowledge, its role in the occurrence of
cachectic features associated with leukemia progression has never
been investigated. In this study, we bring experimental evidence
supporting the concept that the gut microbiota interacts with host
tissues to control leukemia-related inflammation and induction of
muscle atrophy markers. In fact, we propose that, in an acute
Table 2. Body weight gain, leukemia- and fat mass-related parameters, blood glucose and lipids.
Control Lrg BaF3 BaF3-Lrg
Body weight gain (g) 1.6760.32 2.0060.18 1.6560.19 1.5160.30
Liver weight (g) 0.9760.03a 1.0060.03a 2.3160.04b 2.0760.13b
Spleen weight (g) 0.0860.01a 0.0860.01a 0.8560.02b 0.8460.04b
Hepatic Bcr-Abl mRNA levels (relative expression) ND ND 1.0060.10 1.0760.13
Change in fat mass (g) 0.5060.09a 0.5860.18a 21.3560.09b 20.9360.15b
Ovarian adipose tissue (g) 0.2660.02a 0.2660.02a 0.1260.01b 0.1360.01b
Subcutanous adipose tissue (g) 0.3060.02a 0.3360.02a 0.2060.01b 0.2060.01b
Glycemia (mM) 5.4260.20ab 5.6760.18b 4.4260.35c 4.5860.23ac
Plasma cholesterol (mM) 1.6060.06a 1.6160.05a 0.9660.06b 1.0760.09b
Plasma triglycerides (mM) 1.4660.16 1.5860.14 1.3160.13 1.0560.09
N= 7–8, data with different superscript letters are significantly different (p,0.05). ND = not detected.
doi:10.1371/journal.pone.0037971.t002
Figure 4. Supplementation with Lactobacillus reuteri 100-23 and Lactobacillus gasseri 311476 mixture reduces inflammatory
cytokines. A–F. Plasma levels of interleukin 4 (IL-4), interleukin 10 (IL-10), interleukin 6 (IL-6), monocyte chemoattractant protein 1 (MCP-1),
interleukin 8 (IL-8), and granulocyte colony-stimulating factor (G-CSF) in control mice (CT), in mice receiving lactobacilli (Lrg), in mice transplanted
with BaF3 cells (BaF3) and in mice transplanted with BaF3 cells and receiving lactobacilli (BaF3-Lrg). Data with different superscript letters are
significantly different (p,0.05).
doi:10.1371/journal.pone.0037971.g004
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leukemia mouse model, i) dysbiosis occurs, ii) a lower level of
specific lactobacilli in the gut is associated with muscle atrophy
markers and pro-inflammatory processes occurring upon leukemia
progression and iii) counteracting the drop in the level of the
Lactobacillus reuteri and gasseri/johnsonii using a selected probiotic
approach reduces serum pro-inflammatory cytokines and decreas-
es muscle atrophy marker expression.
We show here for the first time that the gut microbiota
composition is modified during leukemia progression. In this
mouse model, Lactobacillus spp. levels decrease by a factor of fifty,
affecting specific lactobacilli species such as L. johnsonii/gasseri, or L.
reuteri, whereas other groups remain unchanged (L. murinus/
animalis). Such specific changes inside the Lactobacillus genus have
previously been reported in a genetic mouse model of colitis [40].
The authors suggested as a mechanism a change in the availability
of a L. reuteri specific substrate.
Crawford et al. demonstrated that a 24-hour starvation period
was enough to significantly modify the mouse gut microbiota
composition in favor of an increased proportional representation
of the Bacteroidetes and a decrease in Firmicutes [41]. Therefore, we
performed a dietary restriction experiment which allowed us to
conclude that the decreased lactobacilli levels could not be
explained by the decreased food intake, but were clearly linked to
another phenomenon, associated with the progression of the
disease.
To counteract the reduced numbers of lactobacilli, and to assess
the relevance of this reduction on systemic alterations occurring in
leukemic mice, we performed a probiotic approach consisting in
the oral administration of two live lactobacilli. We used strains
which belong to the species whose levels were decreased in the
BaF3 mice, L. reuteri 100-23 and L.gasseri 311476. Interestingly, L.
reuteri and L. gasseri restoration decreased the plasma level of
inflammatory cytokines (IL-4, MCP-1, IL-6, G-CSF) and main-
tained the plasma level of the anti-inflammatory IL-10. The ability
of specific Lactobacillus strains, including L. reuteri 100-23, to
modulate inflammation and systemic immunity is now clearly
established [34,36,42,43]. Lactobacilli counts were reduced in
leukemic mice and this decrease correlated negatively with the
atrophy markers in the muscle. Pro-inflammatory cytokines, such
as IL-6 or TNF-a, have been proposed to contribute to muscle
atrophy [1]. Of note, experiments revealed that TNF-a level was
not increased in the plasma of BaF3 mice (data not shown). IL-4 is
the most powerful cytokine that can initiate T helper 2 cell
differentiation [44]. The anti-inflammatory effect of the selected
lactobacilli, including decreased Th2 immunity, could contribute
to the reduction in atrophy marker expression in both gastrocne-
mius and tibialis muscles. This reduction in the muscle atrophy
marker expression could be of interest in therapeutics. Indeed,
reducing atrophy markers, in vivo or in vitro, directly or indirectly,
attenuates muscle atrophy [45–47]. This effect, however, might be
strain- and/or species-specific since it was not observed with e.g.
Lactobacillus acidophilus NCFM. Because beneficial properties of
lactobacilli are known to be strain-specific [36], we hypothesize
that the inflammatory properties of the strain could constitute a
Figure 5. Supplementation with Lactobacillus reuteri 100-23 and Lactobacillus gasseri 311476 mixture reduces muscle atrophy
markers. A–D. Atrophy marker expression (Atrogin-1, MurF1, LC3 and Cathepsin L) measured in the gastrocnemius muscle of control mice (CT),
mice receiving lactobacilli (Lrg), mice transplanted with BaF3 cells (BaF3) and mice transplanted with BaF3 cells and receiving lactobacilli (BaF3-Lrg).
E–H. Atrophy marker expression (Atrogin-1, MurF1, LC3 and Cathepsin L) measured in the tibialis muscle. F. Muscle weights. N = 7–8. Data with
different superscript letters are significantly different (p,0.05).
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rational argument for the probiotics selection for the future
experiments.
Lipopolysaccharides (LPS) are pro-inflammatory compounds of
bacterial origin [48]. They are able to induce muscle atrophy in
vivo and in vitro [49] and are increased in the serum of acute
leukemic patients [50]. In the present study, we did not find
significant modification in serum LPS (data not shown). This
suggests that the pro-inflammatory process is not dependent, in
this model, on LPS translocation across the gut barrier.
Concerning the cancer progression itself, inflammatory medi-
ators such as cytokines and chemokines could in some cases play
opposite roles on cancer progression through their action on
survival pathways and metastasis. Generally, inflammation is
considered as pro-tumorigenic [51,52]. An anti-inflammatory
approach thus arouses full interest in the field of cancer therapy
[51]. In our model, decreasing inflammation through specific
lactobacilli supplementation did not impact on leukemia progres-
sion, but seemed to selectively target the muscle tissue by
decreasing the muscle atrophy marker expression.
In conclusion, we highlighted that the gut microbiota compo-
sition is modified in a mouse model which mimics acute leukemia.
Moreover, we illustrate that restoring the Lactobacillus levels by
adding specific strains reduces the inflammation, an effect
correlated with the improvement of skeletal muscle atrophy
markers. Our data open a new door to understanding the
mechanisms underlying the gut microbiota-host interplay in the
context of systemic cancers. Obviously, the role of the gut
microbiota in systemic immunity and related muscle disorders, as
well as the existence of intestinal dysbiosis, warrants further
investigations in leukemic patients, before proposing novel
therapeutic approaches.
Supporting Information
Figure S1 The decreased food intake observed at the
end of the experiment is not responsible for the
decreased Lactobacillus spp. levels. A. Daily food intake
of mice that received a transplant of BaF3 cells (BaF3) and their
control (CT1); and of dietary restricted (DR) mice and their
control (CT2). N= 4–5. B. Total food intake from day 11 to day
13, N= 4–5. C. Bacteroides spp., Lactobacillus spp., L. johnsonii/gasseri
and L. reuteri levels. N=8–10. *p,0.05 BaF3 vs. CT1, # p,0.05
DR vs. CT2.
(TIFF)
Figure S2 The melt curve shape difference between the
control mice and the BaF3 mice suggests that the
equilibrium inside the Lactobacillus genus is modified.
A, B. Melt curves in derivative form of the PCR amplicons
generated with the Lactobacillus spp. [II] primers. Different peaks
can be assumed to represent differences in % G+C content of the
amplicons (Louis P, Young P, Holtrop G, Flint HJ. (2010).
Diversity of human colonic butyrate-producing bacteria revealed
by analysis of the butyryl-CoA:acetate CoA-transferase gene.
Environ. Microbiol. 12:304–314.).
(TIFF)
Figure S3 Lactobacillus spp. levels are highly correlated
with muscle atrophy markers. A–D. Correlations between
Lactobacillus spp. levels and atrophy marker expression (Atrogin-1,
MuRF1, LC3 and Cathepsin L) measured in the gastrocnemius
muscle. Closed circle for control mice (n = 16); cross for mice
transplanted with BaF3 cells (n = 15–16). The graphs are the result
of two independent in vivo experiments pooled together. Insets
indicate the Pearson correlation coefficient and the corresponding
p-value.
(TIFF)
Figure S4 Unsupervised analysis of the supplementa-
tion with Lactobacillus reuteri 100-23 and Lactobacillus
gasseri 311476. The principal component analysis takes into
account lactobacilli levels, muscle weight, muscle atrophy marker
expression (tibialis and gastrocnemius), and plasma inflammatory
markers. CT = control mice; Lrg = mice receiving lactobacilli;
BaF3= mice transplanted with BaF3 cells; BaF3-Lrg = mice
transplanted with BaF3 cells and receiving lactobacilli.
(TIFF)
Figure S5 Lactobacillus acidophilus NCFM supplemen-
tation does not blunt cachexia. A. Lactobacillus spp. levels in
control mice (CT), in mice receiving L. acidophilus NCFM (Lac), in
mice transplanted with BaF3 cells (BaF3) and in mice transplanted
with BaF3 cells mice and receiving L. acidophilus NCFM (BaF3-
Lac). B. Liver and spleen weight. C–D. Atrophy marker
expression (Atrogin-1 and Cathepsin L) measured in the
gastrocnemius muscle. E–J. Plasma levels of interleukin 4 (IL-4),
interleukin 10 (IL-10), interleukin 6 (IL-6), monocyte chemoat-
tractant protein 1 (MCP-1), interleukin 8 (IL-8) and granulocyte
colony-stimulating factor (G-CSF). N= 8–10. Data with different
superscript letters are significantly different (p,0.05).
(TIFF)
Table S1 Primers and probes sequences used for real-
time quantitative PCR and PCR amplification before
DGGE. Ta: PCR annealing temperature (uC).
(XLS)
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